Quoin Pharma's QRX003 Gets Japan Orphan Drug Designation
Quoin Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to QRX003 for Netherton Syndrome. This designation provides significant development incentives, including up to 10 years of market exclusivity upon approval in Japan. This adds to previous Orphan Drug, Pediatric Rare Disease, and Fast Track Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency. Japan is a strategically important market where Quoin plans to self-commercialize QRX003, with a pivotal Phase 3 study expected to start in the second half of 2026.
Key Highlights
- Japan's MHLW granted Orphan Drug Designation to QRX003 for Netherton Syndrome.
- Designation provides up to 10 years of market exclusivity in Japan upon approval.
- QRX003 previously received US FDA Orphan Drug, Pediatric Rare Disease, and Fast Track Designations.
- QRX003 also received European Medicines Agency Orphan Drug Designation.
- Quoin plans to self-commercialize QRX003 in Japan, US, and Western Europe.
- Pivotal Phase 3 study expected to initiate in H2 2026, with potential NDA filing in 2027.
Price Impact
More from QNRX
Quoin Pharma Establishes Japan Subsidiary for QRX003 Commercialization
Quoin Pharmaceuticals QRX003 Shows Positive Results in Pediatric Netherton Syndrome
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003